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Atypical teratoid rhabdoid tumors (ATRTs) are rare central nervous system tumors that
comprise approximately 1–2% of all pediatric brain tumors; however, in patients less than
3 years of age this tumor accounts for up to 20% of cases. ATRT is characterized by loss
of the long arm of chromosome 22 which results in loss of the hSNF5/INI-1 gene. INI1,
a member of the SWI/SNF chromatin remodeling complex, is important in maintenance
of the mitotic spindle and cell cycle control. Overall survival in ATRT is poor with median
survival around 17 months. Radiation is an effective component of therapy but is avoided
in patients younger than 3 years of age due to long term neurocognitive sequelae. Most
long term survivors undergo radiation therapy as a part of their upfront or salvage therapy,
and there is a suggestion that sequencing the radiation earlier in therapy may improve
outcome. There is no standard curative chemotherapeutic regimen, but anecdotal reports
advocate the use of intensive therapy with alkylating agents, high-dose methotrexate, or
therapy that includes high-dose chemotherapy with stem cell rescue. Due to the rarity of
this tumor and the lack of randomized controlled trials it has been challenging to define
optimal therapy and advance treatment. Recent laboratory investigations have identified
aberrant function and/or regulation of cyclin D1, aurora kinase, and insulin-like growth factor
pathways in ATRT.There has been significant interest in identifying and testing therapeutic
agents that target these pathways.
Keywords: ATRT, pediatric brain tumors, cyclin D1, aurora kinase, insulin-like growth factor, tyrosine kinase
inhibitors
INTRODUCTION
Primary central nervous system (CNS) atypical teratoid rhab-
doid tumors (ATRTs) were identified as a separate entity relatively
recently, as recognized by their addition to the World Health Orga-
nization (WHO) classification of tumors in 1993 (Biernat, 2000;
Radner et al., 2002). The first reported cases appeared as multi-
ple case reports in the late 1980’s and early 1990’s that described
patients, for the first time, with isolated CNS ATRTs (Bonnin
et al., 1984; Biggs et al., 1987; Ho et al., 1990; Chou and Ander-
son, 1991; Agranovich et al., 1992; Satoh et al., 1993). Previously
reported cases of CNS rhabdoid tumors were often associated with
malignant rhabdoid tumors (MRT) of the kidney, which had been
identified a decade earlier upon central review of Wilms’ tumors
treated in a collaborative group (Beckwith and Palmer, 1978).
This group noted that certain patients had tumors with different
pathologic features and that these features were associated with
significantly worse outcomes. Similarly, ATRTs were often cate-
gorized with primitive neuroectodermal tumors (PNETs), along
with medulloblastoma, due to histologic similarities, but they are
now separated from other embryonal tumors by the presence of
rhabdoid cells and specific immunohistochemistry (Biggs et al.,
1987; Lefkowitz et al., 1987; Ho et al., 2000; Bikowska et al., 2011).
Like rhabdoid tumors of the kidney, CNS ATRTs are also associ-
ated with significantly worse overall survival than other embryonal
tumors.
A recent review of the Surveillance, Epidemiology, and End
Results (SEER) database from 1973 to 2008 estimated overall sur-
vival for ATRT patients at 10 months, and notably the year of
diagnosis had no effect on survival, showing that little progress
has been made since ATRTs were first identified (Buscariollo et al.,
2011). Another review from the German HIT database from 1988
to 2004 showed 77% of patients with ATRT (43/56) died of disease
[3-year event-free survival (EFS), 13± 5%; overall survival (OS),
22± 6%; von Hoff et al., 2011]. Investigators from The Hospital
for Sick Children compiled data from four patients with ATRT at
their institution with a retrospective review of 143 cases reported in
the literature from 1995 through 2007 and found a median overall
survival of 17.3 months (Athale et al., 2009). Overall, patients usu-
ally succumb to their disease between 6 months and 1 year from
diagnosis. Survival is especially poor for patients with metastatic
disease, which one registry found was present in around 20% of
patients at diagnosis (Hilden et al., 2004).
ATRT accounts for 1–2% of CNS tumors in children of all ages,
but 10–20% of tumors in patients less than 3 years old (Hilden
et al., 2004; Tekautz et al., 2005; Biegel, 2006), who also tend
to present with infratentorial tumors (70%; Rorke et al., 1996).
The higher frequency of ATRT in patients less than 3 years old
complicates therapy due to avoidance of radiation therapy (RT)
in this age group, and these patients have shorter survival than
older patients with the same tumor. Delayed radiation can affect
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prognosis. Multiple chemotherapy approaches to defer radiation
have been attempted, yet overall survival remains dismal.
In 1995, Rorke et al. (1995) published one of the earliest and
largest case series of 32 infants with CNS ATRT. They found a 1.9:1
male-to-female ratio, a median age at diagnosis of 17 months, and
an association with chromosome 22 abnormalities. In subsequent
years, investigation into associated chromosome 22 abnormalities
led to the identification of hSNF5/INI1 gene mutations that are
now the defining feature of this entity and the main target of cur-
rent research to identify new therapeutic approaches (Versteege
et al., 1998).
This aggressive tumor remains a significant challenge in pedi-
atric neuro-oncology, and new therapeutic approaches are desper-
ately needed. This review will summarize the published therapies
to date and focus on recent basic science and translational studies
as new potential targets are being identified in the laboratory and
there is a need to push for advances in therapy that may lead to
increased survival for patients with this devastating tumor.
CHEMOTHERAPY
Given the rarity of ATRTs and the variety of treatment regi-
mens used to date, no standard therapeutic approach has been
established. Published case series often include patients treated
with multiple therapeutic approaches, making standardization of
therapy difficult. Table 1 summarizes some of the larger clinical
trials that included ATRT patients or that were designed specifi-
cally for ATRT. Early complexity determining the best therapeutic
approach was evident in the reported proceedings of the tumor
board of The Children’s Hospital of Philadelphia (CHOP) in 1991
(Perilongo et al., 1991). The group described a 5-year-old patient
with a CNS primary rhabdoid tumor and detailed their consider-
ation of therapeutic approaches including review of children with
rhabdoid tumors of the kidney. Ultimately, they opted to treat with
3600 cGy craniospinal radiation with an unspecified boost dose to
the primary site along with chemotherapy that was currently in use
on the infant brain tumor therapeutic trials, including cisplatin,
cyclophosphamide, vincristine, and etoposide.
In response to the report from CHOP, Weinblatt and Kochen
(1992) from Cornell submitted a letter describing a patient
they treated in 1985 with a primary CNS rhabdoid tumor with
gross total resection (GTR), 4140 cGy focal radiation, and inten-
sive chemotherapy as per the Intergroup Rhabdomyosarcoma III
(IRS-III) therapy, including weekly vincristine during radiation,
actinomycin-D, doxorubicin, and triple intrathecal chemotherapy
with hydrocortisone, methotrexate, and cytosine arabinoside. An
additional three cases successfully treated with IRS-III were then
reported in 1995 by Ohio State University (Olson et al., 1995). This
approach was justified because ATRT was thought to be similar
to parameningeal rhabdomyosarcomas, requiring more aggres-
sive therapy, and regimen 36 was chosen because it was intensive
chemotherapy that was easily adaptable to radiation and triple
intrathecal chemotherapy. This group also summarized the 18
cases of primary CNS MRTs previously reported in the literature
to date, showing the varied approaches to therapy, and the need
for a more standardized approach.
Dana-Farber Cancer Institute (DFCI) decided to return to
the original early reports of success with IRS-III-based regimens
to treat two new ATRT patients and two with recurrent dis-
ease between December 1999 and April 2002 due to unpublished
reports of failures with modifications from the original therapy
(Zimmerman et al., 2005). DFCI modifications included focal
stereotactic RT without a craniospinal dose for patients less than
3 years old, substitution of dacarbazine with temozolomide, and
addition of dexrazoxane for cardioprotection in higher cumula-
tive doses of doxorubicin. All four patients were alive at the time of
reporting at a median 44.5 months after diagnosis and a median
26.5 months after recurrence. A later update from the group at
DFCI stated that three of the four were alive at a median 6.5 years
after completion of therapy. DFCI then proceeded with a phase II
study between February 2004 and September 2006 with a mod-
ified IRS-III protocol and treated 20 patients with ATRT (Chi
et al., 2009). Eight of the 20 patients had relapses by the time
of publication, giving a 1-year progression-free survival (PFS) rate
of 70± 10% and OS of 75± 10% and 2-year PFS of 53± 13%
and OS 70%± 10%. Univariate analysis showed that PFS and OS
were significantly influenced by the extent of resection. OS was
also affected by tumor location, and patients with posterior fossa
tumors had better survival. The reported PFS and OS were signifi-
cantly better than those seen in other clinical trials but, due to small
numbers, it was impossible to make comparisons to determine
why there was such an improvement. This report did, however,
point to improved survival with intensified chemotherapy that
included intrathecal administration along with focal radiation for
those patients younger than 3 years old. It would also have been
useful with larger numbers to separate the overall survival data
based upon age, as others have shown that survival is improved
for older patients.
Modified IRS-III therapies include intrathecal chemotherapy
as well as multiagent chemotherapy and focal radiation in patients
who have non-metastatic disease. Intrathecal chemotherapy may
have potential benefit as an additional means to avoid radiation
or to intensify therapy in patients who are not candidates for
craniospinal radiation. A meta-analysis by Athale et al. (2009)
showed that even without GTR, patients who received multiagent
chemotherapy fared better, but this effect was most prominent in
those less than 3 years old who did not get radiation. Without radi-
ation, intrathecal chemotherapy also made a significant difference
in overall survival (OS 10.5 months versus 6.5 months, p= 0.011).
An additional approach to early therapy of ATRT was explored
as these patients were included in national infant brain tumor
clinical trials. The North American Children’s Cancer Group from
April 1993 through June 1997 enrolled 299 children less than
3 years old with multiple tumor types on protocol CCG9921
(Geyer et al., 2005). This regimen included two induction courses
with ifosfamide or cyclophosphamide along with vincristine, cis-
platin, and etoposide. Induction was followed by maintenance
with vincristine, etoposide, carboplatin, and cyclophosphamide.
The study included 28 rhabdoid tumors (9.4% of patients
enrolled), and 24 of those had treatment failures. The 1-year and
5-year EFS rates were 32± 9% and 14± 7%, respectively, and the
5-year OS was 29± 9%. Interpretation of factors associated with
prognosis was difficult due to the small numbers in this group.
During the same period, the Pediatric Oncology Group was inves-
tigating the use of standard versus dose-intensified chemotherapy
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Table 1 | Published reviews and clinical trials that included or were specific to atypical teratoid rhabdoid tumors.
Study time
period
n of
patients
Age Type of study Chemotherapy Radiation Survival
Tekautz et al.
(2005)
31 22 patients <3 years
(median 1 year)
Retrospective
review
Multiple regimens <3 years 2 local, 1
CSI+boost
<3 years (estimates)
2-year EFS 11±6%
9 patients ≥3 years 2-year OS 17±8%
July 1984–June
2003
(median 3.9 years) ≥3 years 7 patients
CSI+boost
≥3 years (estimates)
2-year EFS 78±14%
2-year OS 89±11%
Geyer et al.
(2005)
28 12 patients aged
0–11 months.
Phase II/III Induction A (n=16)
VCR/CDDP/CTX/VP
2 patients prior to
progression (1 focal, 1
CSI)
1-year EFS 32±9%
2-year EFS 14±7%
CCG9921 6 patients aged
12–17 months.
Induction B (n=12)
VCR/CDDP/IFOS/VP
5-year EFS 14±7%
5-year OS 29±9%
April 1993–June
1997
10 patients aged
18–36 months.
Maintenance
VCR/CDDP/CTX/VP
Douglas Strother
[personal
communication
2011]
33 All patients <3 years Phase III CTX/VCR/CDDP/VP
Standard versus
dose-intensified
None 5 year OS 0%
Median survival
6.7 months.
POG9233/34
1992–1998
Lafay-Cousin
et al. (2012)
50 Median age 16.7 months. Retrospective
review
Multiple regimens 21 patients at some point
during therapy
2-year OS 36.4±7.7%
17 patients aged
<12 months.
22 conventional
21 patients aged
12–36 months.
18 high-dose chemo 6 patients at time of
relapse
1995–2007 12 patients >36 months.
Chi et al. (2009) 20 Median 26 months
(2.4 month–9.5 years)
Phase II Modified IRS-III 54 Gy focal (n=11) 2-year PFS 53±13%
36 Gy CSI+boost (n=4) 2-year OS 70±10%
2004–2006
CDDP, cisplatin; CSI, craniospinal radiation; CTX, cyclophosphamide; EFS, event free survival; IFOS, ifosfamide; IRS, Intergroup rhabdomyosarcoma study; OS, overall
survival; PFS, progress free survival; VCR, vincristine; VP, etoposide.
to delay radiation in young children on POG 9233/34 (Baby
POG 2). The study enrolled 36 patients with ATRT. Chemother-
apy included cyclophosphamide, vincristine, cisplatin, and etopo-
side. Patients on the dose-intensified arm had better responses,
but all patients with rhabdoid tumors ultimately died, with a
median survival of 6.7 months (personal communication, Douglas
Strother).
Researchers from St. Jude Children’s Research Hospital in 2005
reported a retrospective review of 31 patients with ATRT treated
between 1984 and 2003 (Tekautz et al., 2005). As expected, the
patients were treated with multiple different approaches over
the 20-year period, but overall they determined that outcomes
were better for patients who were older than 3 years at diagnosis
and those who had received craniospinal radiation and high-
dose alkylator-based chemotherapy up front with a 2-year OS
of 89± 11%. Five of the nine patients older than 3 years were
alive without recurrence at the time of publication at a median of
2.2 years, and it is important to note that seven of those patients
had craniospinal radiation. In contrast, only four of 22 patients
less than three were without relapse. One of the four died of a
surgical complication; of the remaining three, two received RT.
The Canadian Pediatric Brain Tumor Consortium recently
published a retrospective review of patients with ATRT treated
from 1995 through 2007 (Lafay-Cousin et al., 2012). They identi-
fied 50 patients, and although there were multiple different thera-
pies during the period, they were able to make several conclusions
from their analysis. As expected, the prognosis was much worse
for patients younger than 12 months. Patients with GTR had bet-
ter survival at 2 years at 60± 12.6% versus 21.7± 8.5% (p= 0.03).
They did not find a significant difference in survival related to
radiation, but they did find that patients treated with high-dose
chemotherapy (HDC) had better 2-year OS at 47.9± 12.1% versus
27.3± 9.5% (p= 0.036).
There seems to be improved survival for those patients treated
on IRS-III based de novo therapy and high-dose alkylating agent
compared to other chemotherapy approaches although numbers
are small in all series and it is difficult to separate the role the
modifications of the IRS-III regimen. As stated earlier, intrathecal
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chemotherapy has been associated with improved survival in those
patients that did not receive radiation. In the IRS-III based reg-
imen, the combination of intrathecal chemotherapy with focal
radiation in those patients less than 3 years of age may be an effec-
tive strategy for disease control, but intrathecal chemotherapy in
those patients older than 3 years may not be needed since cran-
iospinal radiation is an acceptable option. It is clear that intensive
systemic chemotherapy alone as a method to avoid radiation is
not effective in ATRT and radiation must be considered much
earlier in therapy than previously thought appropriate, but with
continued respect for long term effects.
Since 2008, the Children’s Oncology Group (COG) has been
enrolling patients with ATRT on a clinical trial that incorporates
induction chemotherapy with high-dose methotrexate, focal radi-
ation in patients as young as 6 months for infratentorial tumors
and 12 months for supratentorial tumors, and three cycles of con-
solidation with thiotepa and carboplatin with autologous stem
cell support. This therapeutic protocol thus incorporates focal
radiation in younger patients than on previous COG protocols.
High-dose methotrexate was included based on data from the
Head Start (HS) protocols discussed later and the three cycles of
consolidation are based on CCG 99703 for which data has yet to be
published. The study was closed for 1 year due to the toxic death of
one patient but has been reopened with amendments concerning
pulmonary toxicity monitoring and increased time between con-
solidation courses. Enrollment is ongoing, and the accrual rate is
as expected for this rare tumor.
RADIATION
Previous studies that aimed to avoid or delay radiation in ATRT
patients less than 3 years old were associated with a very poor
prognosis, and some clinical trials now incorporate focal radiation
in much younger patients than previously thought appropriate.
Radiation has been associated with improved survival in ATRT,
especially in patients who have craniospinal radiation with a focal
boost to the tumor bed. There are two published series that were
intended to address the issue of radiation in patients with ATRT,
and both support radiation as soon after surgery as possible. Other
case series in the literature are not included here, but most show
outcomes are better in patients who received radiation as noted
previously.
St. Jude researchers reviewed 31 ATRT patients treated from
1987 through 2007, which also included some patients previously
reported by Tekautz et al. (2005), and aimed to evaluate pat-
terns of failure and local control with radiation (Pai Panandiker
et al., 2011). Again, patients had varying chemotherapy regimens
and extent of resection, but all were treated with focal radiation
alone or with the addition of craniospinal irradiation (CSI). At
a median follow up of 48 months, the PFS was 32.2± 10%, and
OS was 53.5± 10%. Using a Cox regression model, they showed
that patients with a GTR and stable disease before RT were less
likely to experience an adverse event, while conversely patients
with delayed RT were more likely to experience an event. Delayed
RT was defined as ≥1 month from surgery. Overall survival was
affected only by disease progression before RT in their analy-
sis. Metastatic disease at presentation did not significantly affect
PFS or OS. Those with less than GTR had a local failure rate of
53.3± 14% at 4 years, and those with GTR had a local failure rate
of 17.9± 10%. Of those who had immediate postoperative CSI,
29% (2/7) experienced local failure compared with 58% (7/12) of
those who had delayed postoperative CSI. The six patients younger
than 3 years who were alive at last follow up before publication all
had focal RT.
Seventeen patients with ATRT were treated at Taipei Veterans
General Hospital in Taiwan between January 1990 and December
2003 (Chen et al., 2006). Fifteen of 17 patients had the standard
study regimen of CSI ranging from 2550 to 3600 cGy for prophy-
laxis or 3600 cGy plus a focal boost up to 4400 cGy for spinal
seeding. The total primary dose ranged from 4860 to 5600 cGy.
Two of 17 patients had whole brain radiation with a focal boost.
Patients received varying approaches to chemotherapy before,
during, or after radiation, with the most common chemother-
apy including vinblastine, ifosfamide, and cisplatin. Nine of the
17 received intrathecal chemotherapy with either methotrexate
or nimustine. The median OS was 17 months and 14 (82%) had
relapses with median time from relapse to death of 6 months. The
group found no difference in OS or failure-free survival between
doses more or less than 5000 cGy. Multivariate analysis showed a
significant relationship between the interval between surgery and
RT (p= 0.031) and the time to radiation completion (p= 0.047).
When evaluating the six surviving patients at the time of publica-
tion, three of whom had no evidence of disease, and one of those
who had never received any chemotherapy, they noted that these
patients tended to be older, had a GTR, and completed CSI with a
focal boost.
HIGH-DOSE CHEMOTHERAPY
Table 2 summarizes patients reported in the literature who have
had HDC as a significant element of their therapy for ATRT. For
each study listed in the table, only the patients who proceeded
to the HDC phase of therapy are shown. HDC with autologous
stem cell rescue has been used not only as salvage therapy for
patients with relapsed disease, but also as a method of intensify-
ing initial chemotherapy to delay irradiation in young patients.
St. Jude researchers retrospectively reviewed 27 cases of recur-
rent malignant brain tumors treated with HDC with autologous
stem cell rescue between March 1989 and May 2004. Of the 27
patients treated with multiple chemotherapy regimens, only two
had a diagnosis of ATRT. The estimated 5-year PFS for all embry-
onal tumors in patients less than 3 years old at the time of diagnosis
was 66.7± 22.2% versus 7.1± 4.9% for those 3 years or older. This
difference was likely because the patients younger than three were
able to be salvaged with HDC and radiation, whereas those older
than three had previously received radiation so it was not an option
for salvage. One patient with ATRT who was 1 year old was treated
with chemotherapy alone at diagnosis and had residual tumor
with positive cerebrospinal cytology before HDC. Salvage therapy
included high-dose cyclophosphamide and topotecan; disease per-
sisted after HDC. Time to progression was 39 days, and the patient
died of disease 70 days after salvage therapy. The other patient with
ATRT, also 1 year old, received chemotherapy alone at diagnosis
and had no evidence of disease at time of salvage therapy, which
included focal RT and HDC with cyclophosphamide and topote-
can. At the time of publication, he remained alive with no evidence
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of disease after more than 862 days (Shih et al., 2008). Although it
is difficult to generalize this information, the results are as would
be expected, in that patients with minimal to no detectable disease
at the time of HDC are more likely to have prolonged survival.
Gardner et al. (2008) reported their experience treating patients
with CNS ATRT enrolled on the HS I and II protocols. Thir-
teen patients underwent surgical resection followed by five cycles
of induction chemotherapy and a single course of HDC with
stem cell rescue. HS-II differed from HS-I with the addition of
methotrexate to induction agents including cisplatin, etoposide,
cytoxan, and vincristine. Consolidation chemotherapy included
carboplatin, thiotepa, and etoposide. If the patient had no evi-
dence of disease at the end of induction, regardless of second look
surgery, then the patient proceeded to consolidation. If there was
evidence of residual disease locally or with positive cerebrospinal
cytology, consolidation was followed by RT. Four of 13 patients did
not get all five induction courses, and one patient had no induc-
tion chemotherapy and proceeded straight to consolidation. One
patient treated with HS-II who had only 1 cycle of induction died
of Staphylococcus aureus meningitis. During induction there were
eight episodes of bacterial sepsis among six HS-I patients, and
all seven patients on HS-II had bacterial sepsis. Three of the 13
patients had fungal infections. Only two of the six HS-I patients
and five of the seven HS-II patients went on to consolidation. RT
was utilized in two HS-I and two HS-II patients. All six of the
HS-I patients died of disease, but three of the seven HS-II patients
were alive at the time of publication with no evidence of disease,
and none had RT. There may have been a benefit to patients who
received methotrexate, as all patients on HS-I died of their dis-
ease, whereas the reported EFS for HS-II was 43± 19% at 3 years.
They also further supported that near total or GTR led to better
outcomes than subtotal or partial resection with a significant dif-
ference in OS at 57± 18 versus 0%. The estimated EFS and OS at
3 years was 23± 11%. Although this analysis may show a possible
benefit to the use of methotrexate and further supports better out-
comes with more complete resection, the 3-year estimated EFS is
comparable to that achieved with other therapeutic approaches.
A group from Italy reported eight patients treated on a clini-
cal trial that included radiotherapy; ifosfamide, carboplatin, and
etoposide (ICE); and HDC (Fidani et al., 2009). They had orig-
inally included cyclophosphamide, etoposide, carboplatin, and
thiotepa, but after three of four patients had progressive disease
on this therapy, they decided to exclude these courses and replace
them with additional ICE. Only one of eight patients had metasta-
tic disease at diagnosis, and complete resection was achieved in
three patients. They defined overall survival as the time from the
date of diagnosis until the date of death with a reported OS proba-
bility at 5 years of 50%. The group admits that the patient numbers
were too small to make any real determination of survival com-
pared with historic controls. Of the five patients who were reported
as still alive at the time of publication, one did not proceed to HDC,
one had relapse before HDC, one had relapse after HDC but was
alive with salvage therapy, one proceeded through planned ther-
apy including HDC and has no evidence of disease, and one was
currently on therapy at the time of publication.
Researchers at The Hospital for Sick Children in Toronto
reviewed their experience with HDC in ATRT from 2003 through
2008 and found six evaluable patients (Finkelstein-Shechter et al.,
2010). All six patients had three cycles of carboplatin and thiotepa
conditioning, although there were some differences in other ther-
apies received by each patient. They reported four of six patients
alive with no evidence of disease at a median follow up of
52 months, and three of the four patients did not receive any radi-
ation. A team from the University of California, San Francisco,
reported their experience with HDC in nine patients treated at
their institution between 1997 and 2007 (Nicolaides et al., 2010).
Patients had varied postsurgical therapy and conditioning regi-
mens. They reported two patients alive with no evidence of disease
after 78 and 98 months and one alive with disease after 19 months.
Most recently a group from Korea enrolled nine patients on a
prospective phase I/II trial to investigate tandem transplants in
ATRT with course one including carboplatin, thiotepa, and etopo-
side and course two with cyclophosphamide and melphalan (Park
et al., 2012). During therapy, five of the nine had progressive dis-
ease, and one patient died of disease. The remaining four were
salvaged and preceded to tandem transplants. All patients on this
trial were treated with the same conditioning regimen, which
should make comparison easier, but of the five alive at the time
of reporting, four had some deviation from therapy for salvage
after progression. The protocol was written to allow for salvage
therapies in the event of progressive disease while still allowing
the patient to proceed to HDC. There was only one patient who
proceeded through planned therapy including the post-transplant
radiation without progressive disease. They reported a 3-year
OS of 53.3± 17.3% and EFS of 0% and admitted that radiation
may have been the most important component of therapy in the
survivors.
No real conclusions can be made from published data regarding
the role of high-dose chemotherapy in ATRT due to small patient
numbers, multiple chemotherapy regimens, and additional sal-
vage therapy that often includes radiation. The HS II protocol
does point to increased survival with the addition of high-dose
methotrexate to intensive chemotherapy, one course of high-dose
chemotherapy and avoidance of radiation. This difference is likely
due to additional systemic therapy targeted for better CNS pen-
etration rather than the importance of continued inclusion of
high-dose chemotherapy. Upfront intensive multimodal therapy
for ATRT is needed, but the role of high-dose chemotherapy with
autologous stem cell rescue remains unclear and its use should be
balanced with overall toxicity of therapy.
INVESTIGATING NEW THERAPEUTIC TARGETS
The most often encountered genomic aberration in ATRT is
monosomy 22 or a deletion or translocation of 22q11.2, which
is best identified through fluorescence in situ hybridization (FISH;
Biegel, 2006). Inactivating mutations of the SMARCB1 gene
(hSNF5/INI-1) at 22q11.2 is thought to be a crucial step in tumori-
genesis (Biegel, 2006), but mutations can be identified in only
about 76% of CNS ATRT tumor samples (Biegel et al., 2002). INI1
is one member of the BRG-associated factor (BAF) or SWI/SNF
complex, which are important in chromatin remodeling (Biegel,
2006; Venneti et al., 2011). In 1998, Versteege et al. (1998) reported
their work with 13 cell lines in which they identified the most fre-
quent mutations in the hSNF5/INI1 gene. They compared their
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findings with corresponding primary tumor samples to verify that
the mutations did not occur as a result of in vitro growth. The
identified biallelic alterations corresponded with the “two-hit”
model of oncogenesis. More recently a group has shown through
whole-exome sequencing of 32 samples of rhabdoid tumors,which
included 20 CNS tumors, that the overall mutation rate is relatively
low in primary samples (Lee et al., 2012). The primary rhabdoid
tumor genome was seen as relatively simple, but when three recur-
rent tumor samples were tested and compared to primary samples
the mutation rate was increased eightfold. Other investigators at
the time this genetic link became apparent were looking into the
role of SWI/SNF complexes in cell cycle control. It was shown that
complexes of activated versus inactivated retinoblastoma protein
(Rb) with histone deacetylase (HDAC) and SWI/SNF controlled
cell cycle progression through the G1 and S phases through the
E2F pathway (Zhang et al., 2000). Using malignant rhabdoid cells,
it was shown that ectopic expression of hSNF5/INI1 blocks entry
into S phase, but this effect can be reversed by cyclin D1 or cyclin
E (Versteege et al., 2002).
Since 1998, when the hSNF5/INI1 gene was identified as playing
a role in MRTs, work to understand the mechanism that dri-
ves ATRT has provided potential therapeutic targets. Using the
MON cell line, a group from Albert Einstein College of Medicine
reintroduced INI1 and then analyzed a cDNA microarray to deter-
mine expression changes that may result in new therapeutic targets
(Morozov et al., 2007). They found 63 genes that were upregulated
and 18 that were downregulated. The majority of the downregu-
lated genes were important in mitosis, including topoisomerase II
alpha (TOP2A), aurora A (STK6), polo-like kinase (PLK), kinesin
family member 2C (KIF2C), centromere protein F (CENPF), and
pituitary-tumor transforming gene 1 (PTTG1). They found that
interferon-stimulated genes were significantly increased early after
the reintroduction of INI1. They then treated MON and STA-
WT1 rhabdoid cell lines with interferon-alpha or -beta and found
that, compared with controls, there were reduced cell numbers
and increased flat cells 5–7 days after one round of replating. INI1
reintroduction also resulted in down-modulation of PLK1. With
RNA interference, reduced PLK1 levels in rhabdoid cells resulted
in reduced cell numbers, increased cell size, and altered morphol-
ogy. The researchers concluded that drugs that induce interferons
or target PLK1 or cyclin D1 may be effective. There have been at
least two phase I studies of PLK1 inhibitors (BI 2536 and BI 6727)
in adults with solid tumors to date, and they both seem to be well
tolerated with some element of hematologic toxicity in 15–30% of
patients and at least stable disease in up to 40% of patients (Frost
et al., 2012; Schoffski et al., 2012).
CYCLIN D1
Further investigation into the association of INI1 and cyclin D1
showed that loss of INI1 results in derepression of the transcription
of cyclin D1, which may drive the cell through G1 cell cycle restric-
tion. A group at Albert Einstein College of Medicine generated
Ini1+/− mice and showed that they have an increased incidence
of rhabdoid tumors and there is a derepression of cyclin D1. They
then crossed Ini1+/− mice with cyclin D1−/− mice and found that
without cyclin D1 expression, rhabdoid tumors failed to develop.
When they reintroduced INI1 into Ini1−/− MON cell lines, they
showed repression of cyclin D1 and activation of p16INK4A (Tsiki-
tis et al., 2005). A group at CHOP investigated 25 ATRT and 11
non-CNS MRT samples with confirmed SMARCB1 loss. They
aimed to correlate cell line and animal data with primary tumor
samples, because there had been previous contradictions regard-
ing the relationship between SMARCB1, p16INK4A, and cyclin D1.
When staining for p16INK4A, they found that 17 of 25 (68%) of
ATRT and four of 11 (36%) of non-CNS MRT were negative.
They noted expression of cyclin D1 in 20 of 25 (80%) of ATRT
and 6 of 11 (54%) of non-CNS MRT (Venneti et al., 2011). These
studies showed that cyclin D1 may drive rhabdoid tumors and is
expressed in a majority of primary ATRT tumor samples and may
be an effective therapeutic target.
Research unrelated to ATRT has shown that HDAC inhibitors
such as MS-275 or trichostatin A decrease the expression of cyclin
D1 and can decrease cell proliferation in culture (Rosato et al.,
2003; Hu and Colburn, 2005; Alao et al., 2006). Researchers at the
University of Colorado at Denver used two ATRT cell lines and one
primary short-term culture of a tumor sample to investigate the
effects of three HDAC inhibitors: trichostatin A, suberoylanilide
hydroxamic acid (SAHA), and SNDX-275 (Knipstein et al., 2012).
They showed that all tested HDAC inhibitors decreased prolifer-
ation and that SNDX-275 increased the sensitivity of BT12 and
BT16 cell lines to ionizing radiation. Retinoids such as all-trans
retinoic acid have also been shown in the laboratory to inhibit
cyclins and cyclin-dependent kinases, although the specific tar-
get of inhibition differs with the agent used (Kosaka et al., 2001).
Other vitamin A analogs such as the rexinoid bexarotene have
been shown to decrease the expression of cyclin D1, and this effect
can be reversed by the HDAC inhibitor trichostatin A (Li et al.,
2011). The induction of the transcriptional repressor DEC2 by
bexarotene thus requires histone deacetylation as a method to sup-
press transcription of cyclin D1. Understanding these mechanisms
of action further and the application of these methods to ATRT
cells for further investigation may be warranted. Based on cur-
rent information, the combination of a retinoid with an HDAC
inhibitor should be avoided.
AURORA A
The same group previously discussed from Albert Einstein Col-
lege of Medicine also investigated the role of Aurora A in rhabdoid
tumors (Lee et al., 2011). They used rhabdoid tumor cell lines
MON, STA-WT1, and G401 and first showed that introduction
of INI1 resulted in down-modulation of Aurora A by repression
of gene promoter activity. When using si-Aurora A to down-
modulate Aurora A in the cell lines, they saw a significant decrease
in growth with enlarged cell morphology with 12–15% cell death
in the treated cells and an increase in cleaved caspase 3 prod-
ucts. Using three primary human rhabdoid tumors, two primary
mouse rhabdoid tumors, and a mouse xenograft derived from
the human G401 cell line, they showed that all had a several-
fold increase in Aurora A mRNA and all stained with α-Aurora
A antibody. Later published data from the Pediatric Preclinical
Testing Program (PPTP) showed intermediate to high response
rates in rhabdoid mouse xenograft models treated with the Aurora
A inhibitor MLN8237, with the most significant response seen
in the KT12 cell line (Maris et al., 2010). MLN8237 is currently
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in use in clinical trials for adult and pediatric patients with var-
ied tumors, including leukemia/lymphoma, melanoma, and solid
tumors. There are many other aurora kinase inhibitors in various
stages of clinical trials and with different specificities to Aurora A,
B, or C that may be candidates for clinical trials in patients with
ATRT (Dar et al., 2010).
INSULIN-LIKE GROWTH FACTOR
Positive immunohistochemical staining with IGF-IR and its lig-
and IGF-II has been shown in two ATRT samples and suggests
that an autocrine/paracrine loop is involved in ATRT (Ogino et al.,
2001). Researchers from CHOP wanted to further investigate this
pathway and first confirmed IGF-IR expression in eight formalin-
fixed paraffin-embedded ATRT samples (D’Cunja et al., 2007).
Through Western blotting, they showed IGF-IR was more highly
expressed in ATRT than in normal brain, medulloblastoma, or
glial tumors. BT12 and BT16 cells treated with IGF-IR antisense
oligonucleotides decreased proliferation, increased apoptosis, and
increased chemotherapeutic sensitivity to doxorubicin and cis-
platin. Due to the interest in the IGF-I receptor signaling pathway, a
single case of ATRT was evaluated in Poland for downstream effec-
tors Akt or Erk as they relate to mTOR activation (Jozwiak et al.,
2010). They found that Akt was upregulated while an inhibitor of
Akt, PTEN, was not elevated compared with levels found in control
brain. Members of the Erk cascade were not elevated in this sam-
ple. Others have shown that ATRT cell lines grown in serum-free
media secrete insulin, supporting the autocrine/paracrine theory
and that use of the IGF-IR inhibitor NVP-AEW541 inhibited pro-
liferation and increased caspase 3 activation, although only at a
high concentration (Arcaro et al., 2007). There are several pre-
clinical studies and clinical trials related to the development of
IGF inhibitors, whether through small molecule inhibitors such
as nordihydroguaiaretic acid in prostate cancer (Ozkan, 2011;
Friedlander et al., 2012) or breast cancer (Rowe et al., 2008) or
receptor-inhibiting antibodies in multiple solid tumors (Adam
et al., 2011).
TYROSINE KINASES
Multiple tyrosine kinase inhibitors are available, and they are often
used for non-specific targeting of proliferative pathways in oncol-
ogy. A group in Germany investigated 5 ATRT and 18 non-CNS
MRT samples as well as two cell lines for expression of tyrosine
kinases that are inhibited by imatinib (Koos et al., 2010). Previ-
ously, there was a report that the BT12 cell line had decreased
proliferation after treatment with imatinib, although BT16 was
not affected (Narendran et al., 2008). The German group found
c-Abl staining in all 23 primary tumor samples as well as A204
and G401 cells. Imatinib as well as specific targeting of c-Abl with
siRNA significantly reduced proliferation of both cell lines. The
researchers commented on two ATRT patients treated with ima-
tinib due to tumor expression of platelet-derived growth factor
(PDGF) who did not achieve a response, and they hypothesized
that this, as well as previous failure of response in the BT16 cell
line, may both be related to c-Abl expression.
Three cell lines (BT12, BT16, and KCCF1) had dose-dependent
inhibition of growth when exposed to sorafenib and sunitinib
(Jayanthan et al., 2011). Analysis of the supernatant of cell
culture media contained significant levels of PDGF and vascular
endothelial growth factor. After showing that all three cell lines
were affected by the tyrosine kinase inhibitors as well as irinote-
can alone, the group showed that there are synergistic effects on
cytotoxicity when used in combination. Others have reported that
expression of epidermal growth factor receptor was absent in nine
tumor samples of ATRT tested by FISH and immunohistochem-
istry (Jeibmann et al., 2006) and suggested that this may not be an
effective target in ATRT.
It is difficult to take early preclinical work and translate it
quickly to the clinical realm but this is desperately needed in a
tumor such as ATRT with such dismal outcomes. Newer methods
of high throughput screening and “clinics” of experimental ani-
mals have sped the identification of new effective drugs but again
may not translate into clinical effectiveness. As is always a concern
with preclinical data the use of cultured cell lines may not accu-
rately represent the biology of the primary disease but is a cost
effective means to new target identification. As discussed above,
PLK1 levels have only been investigated in a single cell line and
thus this target has the weakest evidence for proceeding further
with clinical applications. Further work is needed with primary
tumor samples, primary cell culture, and animal models. Aurora
kinase A has the most compelling preclinical data as investiga-
tions have included cell line, primary tumor, and mouse xenograft
models and some investigators have proceeded with clinical trials
using MLN8237 for ATRT. Cyclin D1 is the target with the sec-
ond most interesting preclinical data with cell line work in only a
single cell line but further investigations included a mouse model
showing that cyclin D1 seems necessary for tumor formation. This
was further validated by CHOP with 80% cyclin D1 expression of
25 ATRT primary tumor samples. HDAC inhibitors and retinoids
have been in used in pediatric oncology for many years and may
be quickly applied to ATRT although more specific inhibitors of
cyclin D1 would give better therapeutic information. See Figure 1
for a summary of the current targets identified in this review.
CONCLUSION
ATRT is an aggressive malignancy with poor survival especially in
patients with metastatic disease and in those who are younger
than 3 years old at diagnosis. Multiple therapeutic approaches
have been attempted over the last two decades in an attempt to
increase survival in these patients without much success. RT seems
to be the most important component of therapy but is often not
an option. Survival seems to be better with focal radiation, and
there may be a role for intrathecal chemotherapy in patients who
are not candidates for radiation. There is no accepted standard
chemotherapy, but intensive alkylator-based chemotherapy regi-
mens, regimens with high-dose methotrexate, and regimens that
include HDC with stem cell rescue may be more effective in these
patients. Efforts to delay radiation often fail, and most reported
cases of survivors, even when including HDC with stem cell rescue,
frequently require repeat surgery and radiation.
More potential therapeutic targets have become apparent
as we learn more about the biological mechanisms that drive
tumor formation and proliferation. Cell line data and preclini-
cal mouse models are not ideal but are necessary to determine the
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FIGURE 1 | Potential therapeutic targets in ATRT. Studying the
effects of the reintroduction of INI1 as well as the effects of its loss
has led to the identification of multiple potential therapeutic targets.
INI1 loss leads to increased cyclin D1 which propagates the cell
through the G1-S checkpoint. HDAC inhibitors as well as Vitamin A
analogs such as retinoids and rexinoids have been shown to inhibit
cyclin D1. Aurora A signaling has also been shown to be important in
ATRT and multiple inhibitors of Aurora kinase signaling are available.
IGF-IR signaling may also play a role in ATRT and inhibitors are
available for testing.
effectiveness of chemotherapy and small molecule inhibitors. It is
unlikely that any of these agents alone will result in increased sur-
vival, and they must be combined with current intensive therapy
if they are expected to have any lasting effects. Combinations of
these targeted agents will also likely be required, just as our current
therapy includes chemotherapeutics with different targets to affect
cell cycle progression.
More rapid progression of these agents from the laboratory
to the clinic is needed. Many agents described in this review are
already in clinical use but have not had reported use in ATRT,
and these agents may be able to move forward more quickly into
clinical trials. Current therapy seems to be reaching the maximum
levels of tolerable intensification without bringing a significant
change in outcomes, and new approaches are desperately needed
to advance therapy.
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